Quince Therapeutics Q4 EPS $(0.21) Down From $(0.13) YoY
Portfolio Pulse from Benzinga Newsdesk
Quince Therapeutics (NASDAQ:QNCX) reported a Q4 EPS loss of $(0.21), a 61.54% increase in losses compared to $(0.13) per share from the same period last year.
April 02, 2024 | 12:13 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Quince Therapeutics reported a significant increase in losses for Q4, with EPS at $(0.21) compared to $(0.13) the previous year.
The reported increase in losses for Quince Therapeutics is likely to negatively impact investor sentiment in the short term, as it indicates a worsening financial performance compared to the same period last year.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100